Royal Bank of Canada
VRAX icon

Royal Bank of Canada’s Virax Biolabs VRAX Stock Holding History

Royal Bank of Canada’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-416
Closed -$23K – 7264
2024
Q4 		$23K Buy
+416
New +$19.9K ﹤0.01% 6063
2022
Q4 		– Hold
0
– – – 7769
2022
Q3 		– Hold
0
– – – 7908

Other funds holding VRAX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Royal Bank of Canada's VRAX Position: Q1 2025 in Review

Royal Bank of Canada sold out of Virax Biolabs (VRAX) in Q1 2025, closing a stake of 416 shares — an estimated $23K sold.

Royal Bank of Canada first reported a position in VRAX in Q4 2024 and held it in 1 quarter. The position peaked at $23K in Q4 2024. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2025.

  • Royal Bank of Canada reported no remaining Virax Biolabs position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 416 Virax Biolabs shares in Q1 2025, an estimated $23K.
  • Royal Bank of Canada first reported a position in Virax Biolabs in Q4 2024 and held it in 1 quarter.
  • Royal Bank of Canada's Virax Biolabs position peaked at $23K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.